Omeros Corporation (NASDAQ:OMER – Get Free Report) VP Peter Cancelmo sold 25,000 shares of Omeros stock in a transaction on Friday, August 28th. The stock was sold at an average price of $18.65, for a total transaction of $466,250.00. Following the sale, the vice president owned 200 shares of the company’s stock, valued at $3,730. The trade was a 99.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Omeros Stock Performance
OMER stock traded down $0.04 during midday trading on Tuesday, reaching $18.75. The stock had a trading volume of 2,042,181 shares, compared to its average volume of 1,711,567. The firm has a fifty day simple moving average of $12.81 and a two-hundred day simple moving average of $12.08. Omeros Corporation has a 52-week low of $3.94 and a 52-week high of $19.65. The stock has a market cap of $1.36 billion, a PE ratio of 14.65 and a beta of 2.54.
Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. On average, sell-side analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of equities research analysts recently commented on OMER shares. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.
Get Our Latest Analysis on Omeros
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Read More
- Five stocks we like better than Omeros
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
